Antonio Di Francesco

Antonio Di Francesco

Auto-generated profile, based on publicly available information

Antonio Di Francesco

Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in Psychiatry Research
Verified
Journal Article
Open access
SASofia Francesca Aprile
Sofia Francesca Aprile
ARAlessandro Rodolico
Alessandro Rodolico
AFAntonio Di Francesco
Antonio Di Francesco
SVSofia Varrasi
Sofia Varrasi
IBIrene Bighelli
Irene Bighelli
FCFilippo Caraci
Filippo Caraci
Schizophrenia spectrum disorders significantly impact daily functioning, with antipsychotic medications regarded as the gold standard treatment. However, their efficacy is often limited by side effects and adherence rates. Understanding patient perspectives and subjective experiences, particularly regarding oral versus long-acting injectable (LAI) antipsychotics, is crucial for improving medication outcomes and patient-tailored treatments. A systematic review of qualitative studies was conducted following the ENTREQ guidelines. Data were extracted from PubMed, Scopus, and PsycInfo, with thematic synthesis used to identify key themes in patient-reported experiences. Thirty-nine studies (1.477 patients) were included and analyzed, revealing three core themes: (1) perception and experience of medication, (2) social dynamics and influence, and (3) trust and communication with healthcare providers. Side effects and lack of information were often mentioned by patients. While LAI antipsychotics were linked to symptom stability and functional improvements, many patients lacked adequate information about their effects, contributing to adherence difficulties. Stigma and negative beliefs were common across both oral and LAI formulations, thus determining significant barriers to medication adherence. This review emphasizes that patients' experiences with antipsychotic medications are shaped by three key factors: the environment, the therapeutic relationship, and the drug itself. Two critical areas warrant particular attention: psychoeducation and stigma. Bridging psychoeducational gaps and addressing stigma could significantly enhance treatment adherence and outcomes. Additionally, greater emphasis on providing comprehensive and accurate information about antipsychotic treatment options is essential to support patient-centred care and informed decision-making.

1 November 2024 in Health Expectations
Verified
Journal Article
Open access
ARAlessandro Rodolico
Alessandro Rodolico
AFAntonio Di Francesco
Antonio Di Francesco
PCPierfelice Cutrufelli
Pierfelice Cutrufelli
IBIrene Bighelli
Irene Bighelli
Pasquale CaponnettoPasquale Caponnetto
Pasquale Caponnetto
Maria Salvina SignorelliMaria Salvina Signorelli
Maria Salvina Signorelli
Background: Schizophrenia treatment with antipsychotics often results in side effects that impact adherence and quality of life. Managing these effects remains challenging, as it requires balancing efficacy and tolerability. The Schizophrenia Technological Evaluation of Patient Side Effects (STEP‐SE) app aims to aid side effects monitoring and management through shared decision‐making (SDM).Aim: This study aimed to evaluate the usability of the STEP‐SE app for patients and clinicians in managing antipsychotic side effects.Methods: Sixteen stable outpatients and 14 psychiatrists participated in semi‐structured interviews after using the STEP‐SE app. Questions explored ease of use, information clarity, user needs fulfilment, patient–clinician collaboration, treatment adherence improvement, patient empowerment and clinical utility. Data were analysed thematically.Results: Overall satisfaction with STEP‐SE was high. Both groups found that the tool improved patient involvement, provided reliable information to enhance therapeutic alliance, posed low risks of misunderstanding and had an intuitive interface. Patients felt more motivated and empowered. Clinicians appreciated guideline consistency. Preferences differed regarding data visualization formats.Discussion: STEP‐SE shows potential for aiding SDM on antipsychotic side effects. Patients gained motivation, and clinicians felt reassured. Refinements around mobile access, graphics and features could augment utility. Generalizability is limited given the stable patient sample.Conclusion: Preliminary findings suggest that STEP‐SE effectively engages patients, empowers them and supports clinicians in collaborative side effect management. Further testing with diverse user groups is warranted.Patient or Public Contribution: The current study was designed to gather patient and public feedback for the development of our decision aid tool, STEP‐SE. Participants interacted with the tool's prototype in interactive sessions, providing insights and identifying technical issues. Their feedback was crucial for enhancing the tool, with each suggestion and bug report carefully considered for future iterations. The participants’ contributions were key in optimizing STEP‐SE's features and ensuring its relevance and reliability. We thank all who shared their time and perspectives, significantly shaping the tool's user‐centred design.

6 June 2024
Verified
Report
Closed access
AFAntonio Di Francesco
Antonio Di Francesco
PCPierfelice Cutrufelli
Pierfelice Cutrufelli
CCCecilia Chiarenza
Cecilia Chiarenza
LZLuca Zambuto
Luca Zambuto
CCCarmen Concerto
Carmen Concerto
MSMaria Salvina Signorelli
Maria Salvina Signorelli
INPLASY20260019 CBD for the treatment of positive and negative symptoms in schizophrenia spectrum disorders – A systematic review and meta-analysis Keywords: Cannabidiol, schizophrenia, posit…

9 January 2024
Verified
Report
Closed access
Carmen ConcertoCarmen Concerto
Carmen Concerto
CCCecilia Chiarenza
Cecilia Chiarenza
AFAntonio Di Francesco
Antonio Di Francesco
SLStefania Lanzafame
Stefania Lanzafame
LMLudovico Mineo
Ludovico Mineo
Maria Salvina SignorelliMaria Salvina Signorelli
Maria Salvina Signorelli
INPLASY202410030 Transcranial Magnetic Stimulation (TMS) for the treatment of amphetamine and amphetamine-type stimulants (ATS) addiction – A systematic review and meta-analysis Keywords: Amphetami…

9 March 2024
Verified
Report
Closed access
AFAntonio Di Francesco
Antonio Di Francesco
CCCecilia Chiarenza
Cecilia Chiarenza
CCCarmen Concerto
Carmen Concerto
ACAlessia Ciancio
Alessia Ciancio
SLStefania Lanzafame
Stefania Lanzafame
APAntonino Petralia
Antonino Petralia
INPLASY202430031 A Narrative Review on the efficacy of different Transcranial Magnetic Stimulation (TMS) protocols for smoking cessation Keywords: Nicotine, tobacco, smoking, dependence, TMS, Non-I…

30 May 2025
Verified
Report
Closed access
AFAntonio Di Francesco
Antonio Di Francesco
ARAlessandro Rodolico
Alessandro Rodolico
AMAntonio Munafò
Antonio Munafò
RCRuggero Cavallaro
Ruggero Cavallaro
CCCristiano Cutuli
Cristiano Cutuli
SLStefan Leucht
Stefan Leucht
INPLASY202550095 Pharmacological, nutraceuticals and supplementation interventions for Treating Weight gain in Schizophrenia. A systematic review and Network Meta-analysis Keywords: Schizophrenia, …